文献速递真菌感染艾滋病与性传播感染

乌干达HIV治疗失败者中隐蔽性抗原血症的筛查研究

Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy-Experienced Ugandans With Virologic Failure.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该研究对1186名接受抗逆转录病毒治疗但病毒学失败的乌干达成人进行回顾性血浆隐蔽性抗原检测,发现3.0%为抗原阳性,且病毒载量≥5000 copies/mL者抗原阳性率显著更高。作者建议在CD4<100 cells/μL之外,对治疗失败且病毒载量≥5000 copies/mL者考虑反射性抗原筛查。

要点

  • 病毒学失败者中隐蔽性抗原血症患病率为3.0%。
  • 病毒载量≥5000 copies/mL者抗原阳性率4.2%,<5000者为0.7%。
  • 抗原阳性者6个月无脑膜炎生存率为61%。

核心结论

  • 在乌干达病毒学失败的ART经治者中,隐蔽性抗原血症患病率为3.0%。
  • 除CD4<100 cells/μL外,对病毒载量≥5000 copies/mL的治疗失败者应考虑反射性抗原筛查。

研究设计与样本

  • 回顾性研究,对2017年9月至2018年1月期间病毒载量检测后剩余血浆进行全国性抗原检测。
  • 纳入1186名病毒学失败(≥1000 copies/mL)的乌干达ART经治成人。

主要发现

  • 1186名受试者中35人(3.0%)抗原阳性,中位ART duration 41个月(IQR 10-84)。
  • 25名有6个月结局者中16人(64%)存活,7人(28%)死亡,2人(8%)失访。
  • 抗原阳性者中91%(32/35)病毒载量≥5000 copies/mL,抗原阴性者为64%(735/1151)(OR 6.0 [95%CI 1.8-19.8];P=.001)。
  • 病毒载量≥5000 copies/mL者抗原阳性率为4.2%(32/768),<5000 copies/mL者为0.7%(3/419)。
  • 6个月无脑膜炎生存率为61%(14/23)。

关键数值与推荐

  • WHO推荐对CD4<100 cells/μL的HIV阳性起始ART者进行抗原筛查。
  • 本研究建议对治疗失败且病毒载量≥5000 copies/mL者考虑反射性抗原筛查。

临床怎么用

  • 对ART经治且病毒学失败(≥1000 copies/mL)的HIV感染者,尤其病毒载量≥5000 copies/mL时,可考虑隐蔽性抗原筛查。
  • 抗原阳性者需评估脑膜炎症状并给予相应抗真菌治疗或预防。

局限性

  • 回顾性研究设计。
  • 部分抗原阳性者缺乏6个月结局数据(35人中仅25人有结局)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Detectable serum or plasma cryptococcal antigen (CrAg) precedes symptomatic cryptococcal meningitis. The World Health Organization recommends CrAg screening for human immunodeficiency virus-positive persons with CD4 count <100 cells/μL initiating antiretroviral therapy (ART). However, an increasing proportion of patients with cryptococcosis are now ART experienced. Whether CrAg screening is cost-effective in those with virologic failure is unknown. METHODS: We retrospectively performed nationwide plasma CrAg testing among ART-experienced Ugandan adults with virologic failure (≥1000 copies/mL) using leftover plasma after viral load testing during September 2017-January 2018. For those who were CrAg positive, we obtained ART history, meningitis occurrence, and 6-month survival via medical records review. RESULTS: Among 1186 subjects with virologic failure, 35 (3.0%) were CrAg positive with median ART duration of 41 months (interquartile range, 10-84 months). Among 25 subjects with 6-month outcomes, 16 (64%) survived, 7 (28%) died, and 2 (8%) were lost. One survivor had suffered cryptococcal meningitis 2 years prior. Two others developed cryptococcal meningitis and survived. Five survivors were known to have received fluconazole. Thus, meningitis-free survival at 6 months was 61% (14/23). Overall, 91% (32/35) of CrAg-positive persons had viral load ≥5000 copies/mL compared with 64% (735/1151) of CrAg-negative persons (odds ratio, 6.0 [95% confidence interval, 1.8-19.8]; P = .001). CrAg prevalence was 4.2% (32/768) among those with viral loads ≥5000 copies/mL and 0.7% (3/419) among those with viral loads <5000 copies/mL. CONCLUSIONS: In addition to the CD4 threshold of <100 cells/μL, reflexive CrAg screening should be considered in persons failing ART in Uganda with viral loads ≥5000 copies/mL.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mpoza E, Rajasingham R, Tugume L, et al. Cryptococcal Antigenemia in Human Immunodeficiency Virus Antiretroviral Therapy-Experienced Ugandans With Virologic Failure. Clin Infect Dis. 2020. PMID: 31679007. doi:10.1093/cid/ciz1069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。